ArticleJournal of diabetes research2026
Polydatin Reverses Diabetes-Induced Apoptosis of Pancreatic β-Cells by Inhibiting the TNF/TNF-R1/Caspase-3 Signaling Axis.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic β-apoptosis is a critical pathological event in diabetes mellitus (DM), yet effective therapeutic agents that directly protect β-cells are lacking. Polydatin (PD), a natural stilbenoid, has shown potential in regulating glucolipid metabolism; however, its role and mechanism in protecting pancreatic β-cells from apoptosis remain largely unexplored.
objectiveThe present work focused on investigating whether PD prevents pancreatic β-cells against diabetes-related apoptosis and exploring the associated molecular mechanisms, with a particular focus on the TNF/TNF-R1/caspase-3 signaling axis.
methodsNetwork pharmacology and bioinformatics were applied in combination with experimental validation. Potential targets of PD and DM were retrieved from public databases. Key candidate targets were screened via protein-protein interaction (PPI) analysis, least absolute shrinkage and selection operator (LASSO) regression, functional enrichment (GO/KEGG), differential expression, receiver operating characteristic (ROC), and clinical correlation analyses. Binding interactions were assessed by molecular docking alongside dynamic simulations. In vitro and in vivo DM models were established with high glucose (HG)-stimulated MIN6 β-cells and high-fat/HG diet-fed mice with low-dose streptozotocin (STZ) administration, respectively.
resultsTNF was identified as a central target of PD against DM, with elevated expression under diabetic conditions and a significant correlation with fasting blood glucose levels. PD exhibited strong binding affinity to both TNF (Vina score: -8.9 kcal·mol
conclusionThis study revealed that PD attenuated diabetic β-apoptosis, likely through inhibition of the TNF/TNF-R1/caspase-3 pathway, suggesting that PD may be a novel anti-DM therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.